{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319358185984.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1182/blood.v76.1.1.1"}},{"identifier":{"@type":"URI","@value":"http://ashpublications.org/blood/article-pdf/76/1/1/603655/1.pdf"}}],"dc:title":[{"@value":"Surface-dependent reactions of the vitamin K-dependent enzyme complexes"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title>\n               <jats:p>During the past 20 years contributions from many laboratories have led to the development of isolation procedures, delineation of primary structures, and more recently, to the expression of recombinant proteins associated with the coagulation cascade. In general, studies of coagulation proteins under defined conditions have demonstrated the prescience of Davie and Ratnoff and MacFarlane in their proposals of the coagulation cascade. The more recent discovery of thrombomodulin by Esmon et al has led to the identification and characterization of components of the vitamin K-dependent anticoagulant pathway. In this review we have attempted to analyze and compare the functional properties of each of the vitamin K-dependent enzyme complexes associated with the procoagulant and anticoagulant phases of blood clotting. Although dissimilarities exist, the vitamin K-dependent complexes have analogous requirements and appear to function with a common general mode of organization. Membrane-bound cofactors serve as anchoring sites for the appropriate membrane-binding enzymes. This process localizes the complex on the membrane surface and increases the catalytic efficiency for substrate utilization. Complex formation provides extraordinary improvements in the catalytic efficiency for the complexes as compared with their soluble enzyme components. Membrane- bound complexes provide a mechanism that can be regulated at a site by membrane presentation, zymogen activation, and cofactor activation or presentation. The kinetic constants obtained for the various coagulation reactions determined in vitro provide some insights into how these pathways may function in vivo. The catalytic efficiency (kcat/Km) for factor X activation by factor VIIIa/factor IXa is far in excess of the catalytic efficiency of activation of factor X by tissue factor/factor VIIa (Table 3). This may provide a rational interpretation for the observation that patients with hemophilia A and B bleed even though they appear to have an alternative pathway to factor X activation. In addition, tissue factor is not ordinarily presented by the vascular tissue that has direct access to blood. However, it appears that extravascular constitutive tissue factor is available once the blood vessel becomes disrupted. The efforts to identify the initiating reactions of the blood coagulation process have not been unambiguously successful. We conclude that factor VII is most likely a zymogen, just as are the other proenzymes of the blood clotting process. In addition, it is difficult to rationalize the importance of the intrinsic pathway of coagulation involving factor XII, prekallikrein, and high molecular weight kininogen since the congenital absence of any one of these factors does not result in abnormal bleeding.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380009142434726533","@type":"Researcher","foaf:name":[{"@value":"KG Mann"}],"jpcoar:affiliationName":[{"@value":"Department of Biochemistry, University of Vermont, Burlington 05405."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319358185856","@type":"Researcher","foaf:name":[{"@value":"ME Nesheim"}],"jpcoar:affiliationName":[{"@value":"Department of Biochemistry, University of Vermont, Burlington 05405."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319358185985","@type":"Researcher","foaf:name":[{"@value":"WR Church"}],"jpcoar:affiliationName":[{"@value":"Department of Biochemistry, University of Vermont, Burlington 05405."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319358185986","@type":"Researcher","foaf:name":[{"@value":"P Haley"}],"jpcoar:affiliationName":[{"@value":"Department of Biochemistry, University of Vermont, Burlington 05405."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319358185987","@type":"Researcher","foaf:name":[{"@value":"S Krishnaswamy"}],"jpcoar:affiliationName":[{"@value":"Department of Biochemistry, University of Vermont, Burlington 05405."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00064971"},{"@type":"EISSN","@value":"15280020"},{"@type":"PISSN","@value":"https://id.crossref.org/issn/00064971"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00064971"}],"prism:publicationName":[{"@value":"Blood"}],"dc:publisher":[{"@value":"American Society of Hematology"}],"prism:publicationDate":"1990-07-01","prism:volume":"76","prism:number":"1","prism:startingPage":"1","prism:endingPage":"16"},"reviewed":"false","url":[{"@id":"http://ashpublications.org/blood/article-pdf/76/1/1/603655/1.pdf"}],"createdAt":"2019-10-13","modifiedAt":"2019-11-19","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002218143636992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factor (F)<scp>VIII</scp>/<scp>VII</scp>a enhances global haemostatic function in the co‐presence of bypassing agents and <scp>FVIII</scp> among patients with haemophilia A with inhibitor"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002218715436160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235483277568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235793753984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235793813504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti‐C2 antibody inhibiting allogeneic but not autologous factor VIII activity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236413005568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236759763968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142434726528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Acidic Region Residues 1680–1684 in the A3 Domain of Factor VIII Contain a Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg1689"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017279867719296","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021390752970880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factor VIII A3 domain residues 1793–1795 represent a factor IXa-interactive site in the tenase complex"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021390754891392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The emicizumab-bridged ternary complex with activated factor IX and factor X evaluated by fluorescence resonance energy transfer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025431112211712","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706498008832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710459468928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Different factor <scp>VIII</scp> neutralizing effects on anti‐factor <scp>VIII</scp> inhibitor antibodies associated with epitope specificity and von <scp>W</scp>illebrand factor"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617409870464","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The C‐terminal acidic region in the A1 domain of factor VIII facilitates thrombin‐catalyzed activation and cleavage at Arg372"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905182579200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567184850574976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643274097280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848659183466496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical feature and anti-phospholipid antibody profiles of pregnancy failure in young women with antiphospholipid antibody syndrome treated with conventional therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848659686449792","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Ribophorin II is involved in the tissue factor expression mediated by phosphatidylserine-dependent antiprothrombin antibody on monocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814739531008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The role of proteolytic cleavage at Arg336 and Arg372 of the A1 domain in factor VIIa/tissue factor-catalyzed reactions of B domain-deleted factor VIII"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869856055660800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Structural Conformation and the Binding of Factor VIII R2159C (FVIII-Ise) Mutated in the C1 Domain to Phospholipid"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204162463872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as a Factor Xa Inhibitor. II. Substituent Effect on Biological Activities."},{"@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as a Factor Xa Inhibitor(2) Substituent Effect on Biological Activities"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204169273216","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors VI. A Series of New Derivatives Containing N,S- and N,SO2-Spiro Acetal Scaffolds"},{"@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors1-6)(6)A Series of New Derivatives Containing N,S- and N,SO2-Spiro Acetal Scaffolds"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204169427456","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors III. Effect of Ring Opening of Piperazinone Moiety on Inhibition"},{"@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors(3)Effect of Ring Opening of Piperazinone Moiety on Inhibition"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679146007936","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors IV. A Series of New Derivatives Containing a Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one Skeleton"},{"@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors(4)A Series of New Derivatives Containing a Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one Skeleton"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679148104576","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors V. A Series of New Derivatives Containing a Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one Scaffold"},{"@value":"Synthesis and Evaluation of 1-Arylsulfonyl-3-piperazinone Derivatives as Factor Xa Inhibitors(5)A Series of New Derivatives Containing a Spiro[imidazo[1,2-α]pyrazine-2(3H),4'-piperidin]-5(1H)-one Scaffold"},{"@language":"ja-Kana","@value":"Synthesis and Evaluation of 1 Arylsulfonyl 3 piperazinone Derivatives as Factor Xa Inhibitors 5 A Series of New Derivatives Containing a Spiro imidazo 1 2 アルファ pyrazine 2 3H 4 piperidin 5 1H one Scaffold"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1182/blood.v76.1.1.1"},{"@type":"CROSSREF","@value":"10.1111/bjh.15209_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1111/bjh.15525_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1111/jth.12660_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1111/jth.13118_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1160/th12-10-0762_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1182/blood-2013-10-530089_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1248/cpb.54.1535_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1248/cpb.55.317_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1055/s-0041-1723996_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1182/bloodadvances.2022008187_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1016/j.bbagen.2023.130381_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1016/j.thromres.2024.03.030_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1182/bloodadvances.2023012391_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1007/s12185-019-02611-3_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1111/bjh.12473_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1160/th11-05-0331_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1248/cpb.50.1187_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1111/jth.15201_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1055/a-2315-8199_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1097/mbc.0000000000000147_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1248/cpb.52.459_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1248/cpb.52.406_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1080/14397595.2017.1386845_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1093/rheumatology/kew005_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1111/jth.12197_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1016/j.bbagen.2023.130501_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"},{"@type":"CROSSREF","@value":"10.1055/a-2509-0511_references_DOI_MMNu4GTUECkuHKWlty7sQ9pTPee"}]}